Healthy Clinical Trial
— COPD-DOPPLEROfficial title:
Femoral Artery Blood Flow During Rest and One-leg Knee Extensor Exercise in Patients With COPD
Verified date | January 2024 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Doppler ultrasound is generally considered to provide reliable femoral blood flow measurements between rest and exercise, and the blood flow response to exercise is widely believed to be reduced in patients with chronic obstructive pulmonary disease (COPD). However, the test-retest reliability of the method during one-leg knee extensor exercise has not previously been compared between matched healthy individuals.
Status | Completed |
Enrollment | 32 |
Est. completion date | January 12, 2024 |
Est. primary completion date | January 12, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years to 80 Years |
Eligibility | Inclusion Criteria for COPD patients: - Men and women - 45-80 years - COPD (GOLD stage I to III) - Forced expiratory volume in 1 sec (FEV1)/forced vital capacity ratio (FVC) < 0.8, FEV1 < 90% of predicted value - Modified Medical Research Council score (mMRC 0 - 3) Resting arterial oxygenation > 90% Exclusion Criteria for COPD patients: - Symptoms of ischaemic heart disease - Known heart failure - Claudication - Symptoms of disease within 2 weeks prior to the study - Participation in pulmonary rehabilitation within 6 months - Known malignant disease - Pregnancy - Unstable cardiac arrhythmic disease - Renal or liver dysfunction Inclusion Criteria for healthy matched controls: - Men and women - 45-80 years - Normal FEV1, FVC, FEV1/FVC, and single-breath diffusion capacity - Same sex, age (± 3 years) as the COPD patients Exclusion Criteria for healthy matched controls: - Known chronic lung disease - Known ischaemic heart disease - Known heart failure - Symptoms of disease within 2 weeks prior to the study - Known malignant disease - Claudication - Pregnancy - Unstable cardiac arrhythmic disease - Renal or liver dysfunction |
Country | Name | City | State |
---|---|---|---|
Denmark | Center for Aktiv Sundhed (CFAS), Rigshospitalet, Copenhagen, Denmark. | Copenhagen | København Ø |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Between-day smallest real difference (SRD) for femoral blood flow at rest and at each relative exercise intensity in COPD vs. healthy controls | Doppler ultrasound measured blood flow during one leg knee extensor exercise with different intensities. | Measured at day 1 and day 2 | |
Primary | • Between-day coefficient of variance (CV) for femoral blood flow at rest and at each relative exercise intensity in COPD vs. healthy controls (co-primary) | Doppler ultrasound measured blood flow during one leg knee extensor exercise with different intensities. | Measured at day 1 and day 2 | |
Secondary | Femoral blood flow response to exercise at each relative exercise intensity in COPD vs. healthy controls (key secondary) | Doppler ultrasound measured blood flow during one leg knee extensor exercise with different intensities. | Measured at day 1 and day 2 | |
Secondary | Between-day smallest real difference (SRD) for femoral blood flow at rest and at each absolute exercise intensity in COPD vs. healthy controls | Doppler ultrasound measured blood flow during one leg knee extensor exercise with different intensities. | Measured at day 1 and day 2 | |
Secondary | • Between-day coefficient of variance (CV) for femoral blood flow at rest and at each absolute exercise intensity in COPD vs. healthy controls (co-primary) | Doppler ultrasound measured blood flow during one leg knee extensor exercise with different intensities. | Measured at day 1 and day 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |